RAPID ADVICE

Antiretroviral therapy for HIV infection in adults and adolescents

NOVEMBER 2009
RAPID ADVICE

Antiretroviral therapy for HIV infection in adults and adolescents
Abbreviations

3TC    lamivudine
ABC    abacavir
ART    antiretroviral therapy
ARV    antiretroviral (drug)
ATV    atazanavir
AZT    zidovudine (also known as ZDV)
bPI    boosted protease inhibitor
CD4    T-lymphocyte bearing CD4+ receptor
CDC    Centers for Disease Control and Prevention
CIPRA HT001 Comprehensive International Program of Research on AIDS in Haiti (clinical trial)
DART Development of Antiretroviral Therapy in Africa (clinical trial)
d4T    stavudine
ddi    didanosine
EFV    efavirenz
FBC    full blood count
FDC    fixed-dose combination
FTC    emtricitabine
GRADE Grading of Recommendations, Assessment, Development and Evaluation
HBAC   Home Based AIDS Care (clinical trial)
HIV    human immunodeficiency virus
HBV    hepatitis B virus
IAS    International AIDS Society
IRIS    immune reconstitution inflammatory syndrome
LPV    lopinavir
NNRTI   non-nucleoside reverse transcriptase inhibitor
NRTI    nucleoside reverse transcriptase inhibitor
NVP    nevirapine
PEPFAR US President’s Plan for Emergency AIDS Relief
PI    protease inhibitor
PMTCT   prevention of mother-to-child transmission
PLHIV   people living with HIV
/r    low-dose ritonavir
RCT    randomized clinical trial
RTI    reverse transcriptase inhibitor
RTV    ritonavir
SAPIT Starting Antiretroviral Therapy at Three Points In Tuberculosis Therapy (clinical trial)
TB    tuberculosis
TDF    tenofovir disoproxil fumarate
VL    viral load
UNAIDS Joint United Nations Programme on HIV/AIDS
WHO    World Health Organization
1. Overview

1.1 Background

The guideline Antiretroviral therapy for hiv infection in adults and adolescents, developed by World Health Organization (WHO), was first published in 2002, simplified in 2003 and was updated in 2006. The guideline continues to follow the principles of a public health approach, aiming to optimize outcomes, including the quality of life and survival, of people living with HIV (PLHIV), and to act as a reference tool for countries to adopt and adapt according to their national circumstances.

During 2009, WHO has worked to update the guideline through a series of coordinated efforts to review and synthesize emerging evidence on when to initiate antiretroviral therapy (ART), what drug regimens to use, and the management of co-infections and treatment failure. This evidence has been assembled following systematic reviews, GRADE profile preparation and analysis, consultations with PLHIV, cost and economic impact studies, country-level feasibility assessment, and comparisons of current country guidelines.

The groups who developed this revised guideline were: an internal WHO ART Guideline Working Group (convened in April 2009), the ART Guideline Drafting Group (convened in September 2009), the external ART Peer Review Panel (convened in September 2009), and the full ART Guideline Review Committee (convened in October 2009). The members are listed in Annex 1.

1.2 Why a revision?

Since the last guideline revision in 2006, new and compelling evidence has become available, particularly concerning the earlier start of ART. There is increasing evidence of improved survival and reduced HIV-related illnesses with the earlier initiation of antiretroviral therapy. Studies support that improved access to ART has a significant impact on the prevention of HIV transmission. Stavudine (d4T) continues to play a critical role in the scaling-up of ART in low- and middle-income countries; however, its cumulative toxicity is unacceptable to PLHIV and to many health care providers. Newer, more patient friendly but currently more expensive ART regimens are available.

The aim of the guideline is to outline standards for high quality care of PLHIV, by providing evidence-based recommendations, while considering the risks and benefits, acceptability, feasibility, cost and financial implications.

1.3 Guiding principles

The ART Guideline Review Committee discussed and agreed upon a set of principles that should be used in developing national treatment recommendations. The principal consideration was that public health interventions should secure the greatest likelihood of survival and quality of life for the greatest numbers of PLHIV.

1. Do no harm
   When introducing changes preserve access for the sickest and most in need.

2. Ensure access and equity
   All clinically eligible people should be able to enter treatment services (including ART) with fair and equitable distribution of treatment services.

3. Promote quality and efficiency
   Ensure delivery of the highest standards of care within a public health approach so as to achieve the greatest health impact with the optimal use of available human and financial resources.

4. Ensure sustainability
   Understand the long-term consequences of change with the vision of providing continued, life-long access to ART for those in need.

In this context, the individual rights of PLHIV should not be forfeited in the course of a public health approach.
2. The revision process

2.1 Retrieving, summarizing and presenting the evidence

The PICO** questions to be considered were agreed upon by the internal WHO ART Guideline Working Group in May 2009. A series of activities then were undertaken to prepare for the October 2009 guideline review meeting:

1. GRADE profiles were prepared for the key PICO questions:
   i. when to start ART;
   ii. what to use in first-line and second-line antiretroviral regimens;
   iii. when to switch to a second-line regimen.

2. Systematic reviews of the literature were conducted on ARV drug interactions with drugs for TB, hepatitis, malaria, and opioids; ART management for HIV/HBV co-infection; ART toxicity summaries for tenofovir, zidovudine, nevirapine and stavudine; the safety of efavirenz; the teratogenicity of efavirenz; a low-dose stavudine safety profile; and reviews of CD4 and viral load laboratory technologies.

3. An impact assessment was conducted to estimate the number of PLHIV in need of treatment according to various proposed CD4 initiation thresholds.

4. Consultations were conducted with three organizations representing PLHIV and the findings summarized.

5. Costing information was prepared based on studies of procurement and production of ARVs.

6. A feasibility assessment was conducted for the introduction of the proposed guideline in Malawi (a similar assessment is ongoing in Tanzania).

7. A report was produced on issues related to adherence to ART for PLHIV, including adolescents.

8. A review was undertaken to study and compare current ART guidelines from 26 countries.

9. ART failure criteria were reviewed using data from ART-LINC and other studies.

The GRADE evidence profiles, and the full set of supporting documentation will be included and or referenced in the guideline.***

2.2 Consensus, external review and updating

Existing recommendations were reviewed and revised at the September 2009 meeting of the ART Guideline Drafting Group. Based on presentations and individual review of the available evidence described above, the group compiled risk-benefit analysis for each area of interest. A table that includes the following domains: existing recommendations; new recommendations; quality and grade of evidence for the critical outcomes (mortality, disease progression and serious adverse events); benefits; risks; values; acceptability; costs; feasibility; gaps and research needs was prepared for each set of recommendations. Disagreements were debated during plenary and group sessions and consensus sought.

The ART Peer Review Panel reviewed and revised the risk-benefit tables and draft recommendations prepared by the ART Guideline Drafting Group and responded with their comments and other input via the ART Guidelines 2009 page of WHO’s EZCollab website. Reviewers debated and exchanged ideas within EZCollab and during teleconferences. Their suggestions and comments were collated and posted on the EZCollab website. The revised recommendations were presented to the ART Guideline Review Committee in October 2009.

At the October 2009 ART Guideline Review Meeting, each subject area was reviewed, discussed and consensus sought on each recommendation and the ranking of each recommendation.

The full guideline document will be reviewed again by 2012.

** PICO is an acronym that describes the elements of a well-formed clinical question. The structure includes: ‘P’ for the patient or population; ‘I’ for the intervention of interest; ‘C’ for comparison; and ‘O’ for outcome.

*** The full set of background materials can be requested by emailing hiv-aids@who.int.
3. Guideline timing and publication

This Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents will be published online. Given the short life-span of the Rapid Advice, it will be posted online in English. However, requests from WHO Regional Offices for translation into other languages will be supported from WHO Headquarters.

It is expected that a draft of the full guideline will be available in February 2010 for final clearance, with publication and dissemination anticipated to start in March or April 2010.
4. Dissemination, adaptation, implementation and evaluation

WHO is working closely with WHO Regional and Country Offices, UN and other implementing partners to plan for rapid dissemination, adaptation and implementation of the new recommendations. Much experience has been obtained from previous ART guidelines, and active support for guideline revision at country level is needed. Key steps in the dissemination include:

- Release of the *Rapid advice*
- Production and publication of the full guideline, with translation into other languages
- Rapid development of adaptation and transition tools
- Briefings and joint planning for dissemination with international and national implementing partners
- Regional conferences and workshops, to support country adaptation

Adaptation and transition tools are designed to:

- Assist countries prioritize limited resources to facilitate full implementation over time
- Not compromise ART access or exclude those most in need
- Not disrupt existing scale up efforts or threaten adherence
- Move progressively towards adopting all recommendations

The WHO and UNAIDS are finalizing the global and country tools required for estimations of treatment and resource needs, in time for 2010 universal access reporting.
5. Declarations of interest

Forms were collected from every member of each group. Two declarations were made and were determined not to constitute conflicts of interest by the core guideline team. The ART Peer Review Panel was advised via the WHO’s EZCollab website of a member’s declaration of potential conflict (P. Cahn) and the ART Peer Review Panel concluded that there was no conflict of interest. The declaration of potential conflict of a member of the ART Guideline Review Committee (C. Holmes) was discussed with the assembled ART Guideline Review Committee at the October 2009 meeting. The ART Guideline Review Committee concluded that there was no conflict of interest.
6. Collaboration with external partners

There are no external collaborators specific to this *Rapid advice*. However, several partners have been engaged in the development of the guideline. All collaborations will be detailed in the full guideline.

Funding to support this work comes from The US President’s Emergency Plan for AIDS Relief (PEPFAR), The United Nations Joint Programme on HIV/AIDS Unified Budget and Workplan (UNAIDS UBW), and specific funds through staff time.
7. Key recommendations

**RECOMMENDATION 1**
When to start

1. Start antiretroviral treatment in all patients with HIV who have CD4 count \( \leq 350 \text{ cells/mm}^3 \) irrespective of clinical symptoms.
   (Strong recommendation, moderate quality of evidence)

2. CD4 testing is required to identify if patients with HIV and WHO clinical stage 1 or 2 disease need to start antiretroviral treatment.
   (Strong recommendation, low quality of evidence)

3. Start antiretroviral treatment in all patients with HIV and WHO clinical stage 3 or 4 irrespective of CD4 count.
   (Strong recommendation, low quality of evidence)

Remarks: In developing these recommendations, the panel placed high value on avoiding death, disease progression and HIV transmission over and above cost and feasibility. The recommendations are supported by moderate quality of evidence for critical patient and public health outcomes from one RCT, the CIPRA-HT001 (a single-centre trial in Haiti) and one post hoc analysis nested in a RCT, the SMART trial (a multicentre study in 33 predominantly high income countries). In the GRADE profile, pooled data from these two studies provide moderate evidence that starting ART at CD4 levels higher than 200 or 250 cells/mm\(^3\) reduces mortality rates in asymptomatic, ART-naive, HIV-infected people. The panel also reviewed large observational data sets from both resource limited and high resource settings which are consistent with data from the RCTs but these did not add to the overall quality of the evidence. The panel considered that starting ART earlier is feasible if introduced in a phased manner, with the speed and completeness determined by health system capacity, HIV burden, ART coverage, equity of access and funding.

Considering the uncertain prognostic value of some WHO clinical stage 2 conditions and recent modelling and observational data suggesting that more than 50% of HIV-infected patients with this clinical stage have a CD4 count \( \leq 350 \text{ cells/mm}^3 \), the panel recommended HIV-infected individuals with WHO clinical stage 1 and 2 should have access to CD4 testing to decide if treatment should be initiated.

**RECOMMENDATION 2**
What to start

Start one of the following regimens in ART-naïve individuals eligible for treatment.

- AZT + 3TC + EFV
- AZT + 3TC + NVP
- TDF + 3TC or FTC + EFV
- TDF + 3TC or FTC + NVP

(Strong recommendation, moderate quality of evidence)

Remarks: In developing these recommendations the panel placed high value on avoiding the disfiguring, unpleasant and potentially life threatening toxicity of d4T, the need to select regimens suitable for use in most patient groups, and the benefits of using fixed dose combinations.

Current evidence suggests that these regimens are comparable in terms of efficacy, with a better overall toxicity profile than d4T based regimens. The panel was reassured by the GRADE profile evidence from RCTs, non-randomised trials and observational studies from low-middle-income countries that indicate no superiority of AZT over TDF, or NVP over EFV as part of combination ART for treatment-naïve individuals.

On the issue of progressive reduction in the use of d4T, in settings where d4T regimens are used as the principal option for starting ART, countries should develop a plan to move towards AZT- or TDF-based first-line regimens, based on an assessment of the cost and feasibility. Systems to prevent, monitor and manage d4T-related toxicities should be implemented.

It is recommended that programs select the preferred regimen(s) applicable to the majority of PLHIV. The introduction of safer but currently more expensive first-line ARTs needs to be phased-in as currently they may not be feasible or affordable in many high-burden settings with low coverage, less developed health systems, limited laboratory capacity, finite budgets and competing health priorities. In countries with high coverage and more developed health systems, transition to new treatment regimens should occur sooner.

WHO will develop tools to assist countries/programs in the transition to and implementation of these recommendations.
RECOMMENDATION 3
ART for HIV/tuberculosis co-infection

1. Start ART in all HIV-infected individuals with active tuberculosis (TB) irrespective of CD4 cell count.
   (Strong recommendation, low quality of evidence)

2. Start TB treatment first, followed by ART as soon as possible after starting TB treatment.
   (Strong recommendation, moderate quality of evidence)

3. Use efavirenz (EFV) as the preferred non-nucleoside reverse transcriptase inhibitor (NNRTI) in patients starting ART while on TB treatment.
   (Strong recommendation, high quality of evidence)

Remarks: In developing these recommendations, the panel placed high value on the reduction of early mortality from HIV/TB co-infection, the reduction of TB transmission when ART is initiated earlier in all individuals with TB and improved management of TB.

On the question of when to initiate ART in TB infection, one RCT (SAPIT trial) provides moderate evidence for early initiation of ART in terms of reduced all-cause mortality, improved TB outcomes and reduced incidence of immune reconstitution inflammatory syndrome (IRIS), but there are limited data on the need to initiate ART in patients with TB and CD4 >350 cells/mm³. On the question of the impact on TB transmission and incidence, ART has been reported to reduce TB rates by up to 90% on an individual level, by 60% at a population level and to reduce TB recurrence rates by 50%. Modeling suggests that initiation of ART for all those with HIV/TB co-infection, if accompanied by high levels of coverage and ART adherence, reduces the number of TB cases, TB mortality rates and TB transmission at a population level. Further modeling suggests that starting ART less than five years after initial HIV infection could reduce the incidence of TB by 60% to 70%. (B Williams, submitted for publication)

On the question of which NNRTI to start, the recommendations in the 2006 ART guideline were maintained, specifically EFV is recommended because of less interaction with rifampicin compared to NVP.

RECOMMENDATION 4
ART for HIV/HBV co-infection

1. Start ART in all HIV/HBV co-infected individuals who require treatment for their HBV infection, irrespective of CD4 cell count or WHO clinical stage.
   (Strong recommendation, low quality of evidence)

1. Start TDF and 3TC or FTC containing antiretroviral regimens in all HIV/HBV co-infected individuals needing treatment.
   (Strong recommendation, moderate quality of evidence)

Remarks: In developing these recommendations, the panel placed high value on promoting HBV diagnosis and more effective treatment of HIV/HBV co-infection.

The systematic review on this topic did not find RCTs which addressed critical HIV outcomes (death, disease progression, severe adverse events) and the GRADE profile reported only on outcomes related to HBV (HBV viral load and HBV drug resistance).

On the question of when to start ART in HIV/HBV co-infection, there are no trials comparing early versus late initiation of ART. However, observational data support that individuals with HIV/HBV co-infection have a 3- to 6-fold risk of developing chronic HBV, an increased risk of fibrosis and cirrhosis and a 17-fold increased risk of death compared to HBV-infected individuals without HIV infection. Similarly, observational data support a reduction in liver related disease with earlier and HBV-active combination ART.

On the question of what ART to start in HIV/HBV co-infection, there are data from one RCT supporting the use of at least two agents with activity against HBV in terms of improved HBV viral load response and reduced development of HBV drug resistance.
RECOMMENDATION 5
ART for pregnant women

1. Start ART in all pregnant women with HIV and CD4 count ≤350 cells/mm³, irrespective of clinical symptoms. 
   (Strong recommendation, moderate quality of evidence)

2. CD4 testing is required to identify if pregnant women with HIV and WHO clinical stage 1 or 2 disease need to start antiretroviral treatment or prophylaxis. 
   (Strong recommendation, low quality of evidence)

3. Start ART in all pregnant women with HIV and WHO clinical stage 3 or 4, irrespective of CD4 count. 
   (Strong recommendation, low quality of evidence)

4. Start one of the following regimens in ART-naïve pregnant women eligible for treatment. 
   (Strong recommendation, moderate quality of evidence)
   - AZT + 3TC + EFV
   - AZT + 3TC + NVP
   - TDF + 3TC or FTC + EFV
   - TDF + 3TC or FTC + NVP

5. Do not start EFV during the first-trimester of pregnancy. 
   (Strong recommendation, low quality of evidence)

Remarks: In developing these recommendations, the ART and PMTCT panels placed high value on ensuring treatment is started early for pregnant women with HIV to avoid mother-to-child transmission and improve maternal and child-health outcomes, over and above concerns for the cost or feasibility.

On the question of when to start, no studies specific to pregnant women were identified. Overall evidence supports strong recommendations for the reduction of mortality, disease progression, severe adverse events, the risk of TB and the risk of HIV transmission (sexual and vertical). As with the recommendation on when to start in the general population, the panel recognised the uncertainty around the prognostic value of some WHO clinical stage 2 conditions and data from modelling and observational studies indicate that more than 50% of HIV-infected patients with this clinical stage have a CD4 count of ≤350 cells/mm³. Therefore, the panel recommended all pregnant women with WHO clinical stages 1 and 2 have access to CD4 testing to decide when to start treatment.

On the question of what to start, no GRADE profiles were prepared as no RCTs were identified for the use of AZT+3TC+NVP specifically in pregnant women. Cohort studies report reduction of HIV transmission and death. There is no evidence to suggest an increase in maternal serious adverse events and no studies specifically evaluating maternal response to ART. Pregnancy registry data on the use of TDF in pregnancy show no signals to raise concern, and there is no evidence to suggest that TDF+3TC or FTC is not an acceptable alternative to AZT+3TC.

There is very low quality, conflicting evidence on the risks of EFV causing neural tube defects. The overall rates of birth defects reported in association with EFV, NVP, lopinavir/ritonavir (LPV/r) or TDF appear similar and are consistent with rates reported in congenital defects’ registries from general populations. Since neural tube closure occurs in the first 28 days and very few pregnancies are recognised by this time, the actual risks from starting EFV based ART in the first trimester are difficult to estimate.

The review of NVP safety in pregnant women with CD4 count 250-350 cells/mm³ did not confirm an increased risk of serious adverse events and the panel concluded that the benefits of using NVP in this situation outweigh the risks of not initiating ART.

The panel was unable to conclude from the evidence reviewed whether there are benefits associated with the use of EFV vis a vis NVP in pregnant women after the first trimester and with higher or unknown CD4 cell counts, although more than half of the panel members preferred EFV in these situations.
RECOMMENDATION 6
When to switch ART

1. Where available, use viral load (VL) to confirm treatment failure.
   (Strong recommendation, low quality of evidence)

2. Where routinely available, use VL every 6 months to detect viral replication.
   (Conditional recommendation, low quality of evidence)

3. A persistent VL above 5000 copies/ml confirms treatment failure.
   (Conditional recommendation, low quality of evidence)

4. When VL is not available, use immunological criteria to confirm clinical failure.
   (Strong recommendation, moderate quality of evidence)

Remarks: In developing these recommendations, the panel was concerned by the limitations of clinical and immunological monitoring for diagnosing treatment failure, and placed high value on avoiding premature or unnecessary switching to expensive second line ART. They also valued the need to optimize the use of virological monitoring and ensure adherence.

Based on the pooled analysis of the size effects from two randomized trials (HBAC and DART trials), clinical monitoring alone (compared to combined immunological and clinical monitoring or to combined virological, immunological, and clinical monitoring) resulted in increases in mortality, disease progression and unnecessary switches, but no difference in serious adverse events. However, in one of these trials (HBAC trial), combined immunological and clinical monitoring was compared to combined virological, immunological, and clinical monitoring, and resulted in no difference in mortality, disease progression, unnecessary switches or virological treatment failures.

RECOMMENDATION 7
Second-line ART

1. A boosted protease inhibitor (PI/r) plus two nucleoside analogues (NRTIs) are recommended for second-line ART.
   (Strong recommendation, moderate quality of evidence)

2. ATV/r and LPV/r are the preferred boosted PI’s for second-line ART.
   (Strong recommendation, moderate quality of evidence)

3. Simplification of second NRTI options is recommended.
   - If d4T or AZT has been used in first-line, use TDF + 3TC or FTC as the NRTI backbone in second-line.
   - If TDF has been used in first-line, use AZT + 3TC as the NRTI backbone in second-line.
   (Strong recommendation, moderate quality of evidence)

Remarks: In developing these recommendations, the panel placed high value on using simpler second-line regimens and the availability of heat-stable, fixed-dose combinations.

On the question of whether PI monotherapy could be used as second-line ART, there is moderate quality of evidence from nine RCTs and individual study reports showing less virological suppression and higher rates of viral rebound for PI monotherapy compared to standard triple ART regimens. The panel concluded that an NRTI backbone should be maintained.

On the question of which bPI to use in second-line therapy, there is moderate quality of evidence that ATV/r is non-inferior to LPV/r (in combination with TDF and an optimized second NRTI) in treatment-experienced patients. Non-serious adverse events varied by boosted PI with no significant difference in serious adverse events.

On the question of which NRTI backbone to use in second-line, few studies of relevance were identified. The recommended NRTI sequencing is based on likely resistance mutations and potential for retained antiviral activity. If AZT+3TC are used in first-line with sensitive monitoring and early switching, the NRTIs with remaining activity are TDF and ddI, (both very likely) and ABC (likely). In the scenario of insensitive monitoring and late switching, TDF and ddI activity are less likely, with activity of ABC unlikely. If TDF+3TC are used in first-line, with early switching, the NRTIs with remaining activity are AZT and d4T (very likely), ddI, ABC (possible). In the scenario of late switching, activity of AZT and d4T is very likely, with activity of ddI and ABC unlikely. Retained activity of 3TC is likely in the early switching scenario and less likely in the case of late switching. AZT+3TC, TDF+FTC and TDF+3TC are available as fixed-dose combinations.
RECOMMENDATION 8
Third-line regimens

1. National programmes should develop policies for third-line therapy that consider funding, sustainability and the provision of equitable access to ART. (Conditional recommendation, low quality of evidence)

2. Third-line regimens should include new drugs likely to have anti HIV activity such as integrase inhibitors and second generation NNRTIs and PIs. (Conditional recommendation, low quality of evidence)

3. Patients on a failing second-line regimen with no new ARV options, should continue with a tolerated regimen. (Conditional recommendation, very low quality of evidence)

Remarks: The panel were concerned by unpublished cohort reports of high mortality among patients failing second-line therapy, but placed high value on balancing the need to develop policies for third-line therapy whilst maintaining increased access to first-line therapy. It was recognized that many counties have financial constraints that might limit the adoption of third-line regimens.

From a targeted literature review of relevant studies, the evidence is limited with few studies of newer agents in resource-limited settings. Data from RCTs predominantly in developed countries are available for boosted darunavir, etravirine and raltegravir. Taken together, these data support the efficacy of these agents in highly ART experienced patients. There was no uncertainty among the panel concerning the need for third-line regimens. However, there was uncertainty about how making third-line regimens available would impact the provision of first-line ART. There was also uncertainty about what third-line drugs should be provided and many studies are ongoing.
8. References


9. Annex 1

WORLD HEALTH ORGANIZATION

2009 ART guideline review meeting
Hotel Ramada Encore, Geneva, 14–16 October 2009

LIST OF PARTICIPANTS
ART Guideline Review Committee

Lori Bollinger (Health Economist)
Vice President
Futures Institute
41-A New London Turnpike
Glastonbury, CT 06033
USA
lbollinger@futuresinstitute.org

Alexandra Calmy (HIV Researcher/Clinician)
Cheffe de clinique scientifique
Service de Maladies Infectieuses
Unité VIH/SIDA
Université de Genève
SWITZERLAND
alexandra.calmy@hcuge.ch

Larry William Chang (Grade Methodologist)
Johns Hopkins School of Medicine
1503 E. Jefferson St.
Baltimore, MD 21287
USA
larrywillchang@gmail.com

Zengani Chirwa (Implementing Partner)
ART Technical Advisor
Ministry of Health,
Lilongwe
MALAWI
czenga@hotmail.com

Francois Dabis
(HIV Researcher/Epidemiologist)
Centre de Recherche INSERM U.897
Institut de Santé Publique, Epidémiologie et Développement (ISPED)
Université Victor Segalen Bordeaux 2
France
francois.dabis@isped.u-bordeaux2.fr

Mathias Egger (HIV Researcher/Epidemiologist)
Professor of Epidemiology & Public Health
Institute of Social & Preventive Medicine
University of Bern
Finkenhubelweg 11
CH-3012 Bern,
SWITZERLAND
egger@ispm.unibe.ch

Shaffiq Essajee (Implementing Partner)
Director of Clinical Operations
Senior Advisor in Pediatrics
Clinton Foundation HIV/AIDS Initiative
USA
sessajee@clintonfoundation.org

Loon Gangte (PLHIV representative)
President,
Delhi, Network of Positive People (DNP+)
Gali No.3, House No-64
Neb Sarai,
New Delhi-1100 68
INDIA
loon_gangte@yahoo.com

Julian Gold (HIV Researcher/Clinician)
Director, Albion St Centre
150 Albion St. Surry Hills NSW 2010
Australia
julian.gold@sesiahs.health.nsw.gov.au

Sarah Glover (HIV Researcher)
London School of Hygiene and Tropical Medicine
Keppel St
London, WC1E 7HT
UNITED KINGDOM
glover_sarah@yahoo.com

James Hakim (Chair/HIV Researcher/Clinician)
Professor
University of Zimbabwe
Harare
ZIMBABWE
jhakim@mweb.co.zw
Sylvia Ojoo (Implementing Partner)
Senior Medical Technical Adviser, AIDSRelief
Institute of Human Virology of the University of Maryland, School of Medicine
KREP Centre, Wood Avenue, Kilimani
PO Box 495, 00606
Nairobi
KENYA
sylvia_ojoo@yahoo.co.uk

Vladimir Osin (PLHIV representative)
Public Relations Manager
Psychological centre “Dvizhenie”
Moscow
RUSSIA
osin.vladimir@gmail.com

Papua Phanuphak (HIV researcher/clinician/implementing partner)
Director
The Thai Red Cross AIDS Research Centre
Co-Director, HIV-NAT
104 Rajdamri Road
Bangkok 10330
THAILAND
praphan.p@chula.ac.th

Bharat Bhushan Rewari (HIV clinician/implementing partner)
Sr. Physician, Dr RML Hospital & National Programme Officer (ART)
National AIDS Control Organisation, 6th Floor, Chandralok Building, 36, Janpath, New Delhi-110001
INDIA
drbrewari@yahoo.com

George Rutherford (Grade Methodologist)
University of California, San Francisco
Institute for Global Health
50 Beale Street, Suite 1200
San Francisco, California 94105
USA
grutherford@psg.ucsf.edu

Papa Salif Sow (HIV researcher/clinician)
Dakar University Hospital
Fann Hospital BP
5035 Dakar
SENEGAL
salifsow@orange.sn

Erik Schouten (implementing partner)
Technical Assistant for Co-ordination of HIV and AIDS Programmes
Department of HIV and AIDS
Ministry of Health
P.O. Box 30377
Lilongwe
MALAWI
eschouten.mm@gmail.com

Tengiz Tsirtsvadze (Programme Implementer)
Director General
Infectious Diseases
AIDS and Clinical Immunology Research Center
National AIDS Coordinator
Tbilisi State University
faculty of Medicine
Tbilisi,
GEORGIA
tengizt@gol.ge

Rochelle Walensky (HIV researcher/health economist)
Harvard Center for AIDS Research
Massachusetts General Hospital
50 Staniford Street, 9th floor
Boston, MA 02114
USA
rwalensky@partners.org

Robin Wood (HIV researcher/clinician)
(UCT), Faculty of Health
26 Orchard Heights, Newlands,
Cape Town
SOUTH AFRICA
Email: robin.wood@hiv-research.org.za
Augustin Okenge Yuma (Programme Implementer)
Directeur
PNLS Programme National de Lutte contre le VIH/SIDA et les ISTTel
Kinshasa
DEMOCRATIC REPUBLIC OF CONGO
dokenge@yahoo.fr

Oleg Yurin (HIV researcher/epidemiologist)
Deputy Head of Federal AYDS Centre, Leading Researcher of Central Institute of Epidemiology/ Moscow RUSSIA
Email: oleg_gerald@mail.ru

Megan O’Brien (HIV researcher)
Clinton Foundation HIV/AIDS Initiative
55 West 125th Street
New York, NY10027
USA
mobrien@clintonfoundation.org

Suzanne Crowe (HIV researcher/laboratory)
Head, Centre for Virology
Burnet Institute
85 Commercial Road, Melbourne, Victoria, Australia 3004
GPO Box 2284, Melbourne, Victoria, AUSTRALIA
crowe@burnet.edu.au

Elliot Raizes (observer)
(implementing partner)
Care and Treatment Branch
NCHSTP/GAP
CDC
MS-E04
1600 Clifton Road NE
Atlanta, GA 3033
USA
gwq0@cdc.gov

WHO staff
Shelley Agarwall
Intern
Antiretroviral Treatment and HIV Care

Silvia Bertagniolo
Medical Officer
Antiretroviral Treatment and HIV Care

Txema Calleja
Medical Officer
Strategic Information

Siobhan Crowley
Acting Coordinator
Antiretroviral Treatment and HIV Care

Micheline Diepart
Medical Officer
Antiretroviral Treatment and HIV Care

Boniface Dongbo
Technical Officer
Systems Strengthening and HIV

Chris Duncombe
Consultant
Antiretroviral Treatment and HIV Care

Sally Girvin
Consultant
Antiretroviral Treatment and HIV Care

Reuben Granich
Medical Officer
Anti-retroviral Treatment and HIV Care

Teguest Guerma
Acting Director
HIV/AIDS Department

Frank Lule
AFRO
UNAIDS staff

Carlos Avila
Adviser
AI/RTN Resource Tracking, Needs and Costing Unit

Anja Grujovic
Technical Officer
AI/AFR AIDS Financing & Economic Division

Jacqueline Ying-Ru Lo
Coordinator
Prevention in the Health Sector

Neil Parkin
Medical Officer
Anti-retroviral Treatment and HIV Care

Francoise Renaud-Thery
Medical Officer
Systems Strengthening and HIV

Nathan Shaffer
Medical Officer
Prevention in the Health Sector

Tin Tin Sint
Medical Officer
Prevention in the Health Sector

Omar Sued
HIV Treatment and Care
PAHO HIV/STI Project (FCH/HI)
525 23rd St. NW
Washington, DC 20037
USA

Yves Souteyrand
Coordinator
Strategic Information

Marco Vitoria
Medical Officer
Antiretroviral Treatment and HIV Care

Dharani Yerrakalva
Intern
Antiretroviral Treatment and HIV Care

Stop TB

Haileyesus Getahun
Medical Officer
TB/HIV and Drug Resistance

Delphine Sculier
Medical Officer
TB/HIV and Drug Resistance
ART Peer Review Panel
2009 revision of Antiretroviral therapy for HIV infection in adults and adolescents

Xavier Anglaret (HIV researcher/epidemiologist)
Senior Researcher
INSERM U897
Université Bordeaux 2
33076 Bordeaux Cedex
FRANCE
Xavier.Anglaret@isped.u-bordeaux2.fr

 Veronica Bortolotti
(programme implementer)
Medical officer, HIV care and treatment and PMTCT
WHO EMRO
AIDS and Sexually Transmitted Diseases (ASD) Unit
World Health Organization
Regional Office of the Eastern Mediterranean
Abdul Razzak Al-Sanhouri St.
P. O. Box 7608 Nasr City
Cairo 11371
EGYPT
Bortolottiv@emro.who.int

Pedro Cahn (HIV researcher/clinician)
Director
Fundacion Huesped
Angel Pellegrino 3932
C1202ABB - Buenos Aires
ARGENTINA
pcahn@huesped.org.ar

Serge Paul Eholié (HIV researcher/clinician)
Unit of Infectious Diseases
Treichville University Hospital
BPV3 CHU Treichville
Abidjan,
IVORY COAST
speholie@afnet.net

Jean-Baptiste Guiard-Schmid (programme implementer)
Inter Country Adviser
World Health Organization
Inter-country Support Team - West Africa
03 BP 7019 Ouagadougou03
BuURKINA FASO
guiardschmidjb@bf.afro.who.int

Mark Harrington (HIV/AIDS policy)
Executive Director
Treatment Action Group
611 Broadway, Suite 308
New York, NY 10012
USA
markhar@gmail.com

Elly Katabira (HIV researcher/clinician)
Professor
Makerere Medical School
Department of Medicine
School of Medicine
Makerere University College of Health Sciences
P. O. Box 7072
Kampala
UGANDA
katabira@imul.com

Ricardo Kuchenbecker (HIV researcher/clinician)
Professor of Medicine
Federal University of Rio Grande do Sul
Hospital de Clinicas de Porto Alegre
Rua Ramiro Barcelos, 2350
90035-903 Porto Alegre, RS
BRAZIL
rkuchen@gmail.com

Barbara Marston (implementing partner)
Medical Officer
Centers for Disease Control and Prevention
1600 Clifton Road
Atlanta GA 30333 MS-E-04
USA
bmarston@cdc.gov
ART Guideline Drafting Group
2009 revision of Antiretroviral therapy for HIV infection in adults and adolescents

Dr Alexandra Calmy (HIV researcher/clinician)
Cheffe de clinique scientifique
Service de Maladies Infectieuses
Unité VIH/SIDA
Université de Genève
SWITZERLAND

Larry William Chang (Grade Methodologist)
Johns Hopkins School of Medicine
1503 E. Jefferson St.
Baltimore, MD 21287
USA
larrywillchang@gmail.com

Dr Tomas Finkbeiner
(HIV clinician/implementing partner)
Director of Clinical Services
CDC
Dar Es Salaam
TANZANIA

Professor James Hakim
(Chair, Guideline Panel, HIV researcher/clinician)
Professor
University of Zimbabwe
Harare
ZIMBABWE

Dr Elizabeth H. Humphreys (GRADE methodologist)
Cochrane Collaborative Group on HIV/AIDS
University of California, San Francisco
USA
Dr Elliot Raizes (Implementing partner)
Care and Treatment Branch
NCHSTP/GAP
CDC
MS-E04
1600 Clifton Road NE
Atlanta, GA 3033
USA

Dr. Paul J. Weidle
(HIV researcher/epidemiologist)
CAPT, USPHS
Research Support Officer
Epidemiology Branch
Division of HIV/AIDS Prevention
National Center for HIV, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
1600 Clifton Rd, MS E-45
Atlanta, GA 30333
USA

UNAIDS staff
Dr Carlos AVILA-FIQUEROA
AI/RTN Resource Tracking, Needs & Costing Unit
UNAIDS

WHO staff
Dr Siobhan Crowley
Acting Coordinator
Anti-retroviral Treatment and HIV Care

Dr Chris Duncombe
Consultant
Antiretroviral Treatment and HIV Care

Dr Jesus Maria Garcia Calleja
Medical Officer
Strategic Information

Mrs Françoise Renaud-Thery
Medical Officer
Systems Strengthening and HIV

Dr Reuben Granich
Medical Officer
Anti-retroviral Treatment and HIV Care

Dr Kerry Kutch
External Relations Officer
HIV/AIDS Department

Ms Sally Girvin
Consultant
Antiretroviral Treatment and HIV Care

Dr Tin Tin Sint
Medical Officer
Prevention in the Health Sector

Dr Marco Vitoria
Medical Officer
Antiretroviral Treatment